Clinical Trial

Anlotinib Plus Toripalimab as First-line Treatment for Advanced Gastric Cancer With ECOG 2 (APICAL-GC)

Unknown Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated July 10, 2024 (before its estimated October 31, 2024 completion). Its status may not reflect the trial's current state.
Summary
This study is designed to evaluate the efficacy and safety of the combination of Anlotinib wiht Toripalimab in advanced gastric cancer with ECOG 2 as first-line regimen.
Protocol Amendment History 1 change
critical Trial status changed: Recruiting → Unknown 2026-08-02
Trial Details
NCT Number NCT04278222
Lead Sponsor Shanghai Changzheng Hospital
Conditions Gastric Cancer, Immunotherapy, Anlotinib, Toripalimab
Enrollment 24 participants
Start Date 2020-02-10
Primary Completion 2024-10-31 (estimated)
Study Completion 2024-12-31 (estimated)
Updated on ClinicalTrials.gov 2024-07-10